The Technical AnalystExchange: STO Sector: Healthcare Industry: Medical Instruments & Supplies
Bonesupport Holding AB Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.66% SEK242.60
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15 944 mill |
| EPS: | 4.08 |
| P/E: | 59.46 |
| Earnings Date: | Jul 10, 2024 |
| SharesOutstanding: | 65.72 mill |
| Avg Daily Volume: | 0.167 mill |
| RATING 2024-05-17 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 3.01x |
| Company: PE 59.46 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 2.86x |
| Company: PE 59.46 | industry: PE 20.76 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
SEK 232.04 - 253.16 ( +/- 4.35%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK242.60 (-0.66% ) |
| Volume | 0.115 mill |
| Avg. Vol. | 0.167 mill |
| % of Avg. Vol | 68.60 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BONEX.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BONEX.ST
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.